4/10
04:05 pm
npce
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
Medium
Report
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
4/1
12:39 pm
npce
How Shifting Margin Assumptions Are Rewriting The NeuroPace (NPCE) Investment Narrative [Yahoo! Finance]
Low
Report
How Shifting Margin Assumptions Are Rewriting The NeuroPace (NPCE) Investment Narrative [Yahoo! Finance]
3/19
06:20 am
npce
NeuroPace (NPCE) was upgraded by Wells Fargo & Company to "strong-buy".
Medium
Report
NeuroPace (NPCE) was upgraded by Wells Fargo & Company to "strong-buy".
3/18
10:32 am
npce
How The NeuroPace (NPCE) Story Is Shifting As Analysts Refresh Valuation Assumptions [Yahoo! Finance]
Low
Report
How The NeuroPace (NPCE) Story Is Shifting As Analysts Refresh Valuation Assumptions [Yahoo! Finance]
3/15
01:05 am
npce
Low
Report
3/7
02:59 am
npce
Low
Report
3/5
04:30 pm
npce
NeuroPace to Present at the Leerink Global Healthcare Conference
Low
Report
NeuroPace to Present at the Leerink Global Healthcare Conference
3/5
07:56 am
npce
NeuroPace (NPCE) was upgraded by Cantor Fitzgerald to "strong-buy".
Low
Report
NeuroPace (NPCE) was upgraded by Cantor Fitzgerald to "strong-buy".
3/4
03:52 pm
npce
Why NeuroPace Stock Was Inching Higher on Wednesday [Yahoo! Finance]
Low
Report
Why NeuroPace Stock Was Inching Higher on Wednesday [Yahoo! Finance]
3/4
12:15 am
npce
NeuroPace Inc (NPCE) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]
Medium
Report
NeuroPace Inc (NPCE) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]
3/3
09:13 pm
npce
NeuroPace, Inc. (NPCE) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
NeuroPace, Inc. (NPCE) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/3
09:10 pm
npce
NeuroPace reiterates $98M–$100M 2026 revenue target while advancing AI and IGE pipeline [Seeking Alpha]
Medium
Report
NeuroPace reiterates $98M–$100M 2026 revenue target while advancing AI and IGE pipeline [Seeking Alpha]
3/3
06:50 pm
npce
NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]
Medium
Report
NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]
3/3
06:25 pm
npce
NeuroPace (NPCE) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
NeuroPace (NPCE) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
3/3
06:25 pm
npce
NeuroPace Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
NeuroPace Q4 Earnings Call Highlights [Yahoo! Finance]
3/3
04:28 pm
npce
NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook [Yahoo! Finance]
High
Report
NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook [Yahoo! Finance]
3/3
04:05 pm
npce
NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook
Low
Report
NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook
3/2
06:03 pm
npce
Global Implanted Brain-Computer Interface Devices Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsight [Yahoo! Finance]
Medium
Report
Global Implanted Brain-Computer Interface Devices Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsight [Yahoo! Finance]
2/24
11:33 am
npce
NeuroPace, Inc. (NPCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release [Yahoo! Finance]
Low
Report
NeuroPace, Inc. (NPCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release [Yahoo! Finance]
2/20
04:42 pm
npce
NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026 [Yahoo! Finance]
Low
Report
NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026 [Yahoo! Finance]
2/20
04:30 pm
npce
NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026
Low
Report
NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026
1/27
07:19 am
npce
NeuroPace (NASDAQ:NPCE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
NeuroPace (NASDAQ:NPCE) had its "buy" rating reaffirmed by analysts at HC Wainwright.